October 5, 2010

Human Genome, Novartis Stop Development of Hepatitis C Treatment

By Jennifer Booton
Published October 05, 2010
FOXBusiness

Human Genome Sciences (HGSI: 30.12 ,+0.65 ,+2.21%) and partner Novartis (NVS: 57.74 ,+0.72 ,+1.26%) have terminated development of their Zalbin drug studied as a potential treatment for chronic hepatitis C.

Development was halted after Rockville, Maryland-based Human Genome received a “complete response letter” from the Food and Drug Administration, often seen as a request for more information regarding a drug application.

The company had a Biologics License Application for 900-mcg Zalbin dosed every two weeks.

In May, the company had said it did not expect to achieve FDA approval at its current dosage.

That view followed a “discipline review letter” in which the FDA voiced safety concerns about the specific dosage.

Source

No comments:

Post a Comment